48,833
edits
Difference between revisions of "Lung cancer after neoadjuvant therapy"
Jump to navigation
Jump to search
Lung cancer after neoadjuvant therapy (view source)
Revision as of 20:11, 21 February 2024
, 21 Februaryno edit summary
| Line 15: | Line 15: | ||
At cut-up the tumour bed was estimated at 5.0 cm. The residual cancer's size is estimated as 1.5 cm (based on a linear measurement of the tumour on slide D15-D16). | At cut-up the tumour bed was estimated at 5.0 cm. The residual cancer's size is estimated as 1.5 cm (based on a linear measurement of the tumour on slide D15-D16). | ||
The estimated viable tumour was assessed in slides D14-D17 and was determined to be: 30%. The estimated viable tumour | The estimated viable tumour was assessed in slides D14-D17 and was determined to be: 30%. The estimated viable tumour EXCEEDS the cut-off value (<=10%); thus, the specimen is NEGATIVE for a major pathologic response.[1] | ||
1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005 | 1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005 | ||
| Line 22: | Line 22: | ||
===At cut-off value for major pathology response=== | ===At cut-off value for major pathology response=== | ||
<pre> | <pre> | ||
The estimated viable tumour was assessed in slides C10-C13 and was determined to be: 10%. The estimated viable tumour is at the cut-off (<=10%) for | The estimated viable tumour was assessed in slides C10-C13 and was determined to be: 10%. The estimated viable tumour is at the cut-off (<=10%) for major pathologic response.[1] Additional sections of the tumour bed are negative; thus, a major pathologic response is favoured. | ||
1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005 | 1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005 | ||